Fuller & Thaler Asset Management, Inc. Sarepta Therapeutics, Inc. Transaction History

Fuller & Thaler Asset Management, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$72.25 - $168.95 $4.61 Million - $10.8 Million	-63,856 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$125.56 - $178.74 $159,712 - $227,357	1,272 Added 2.03%	63,856 $10.9 Million
Q3 2020 Nov 09, 2020	SELL	$127.12 - $172.34 $5.9 Million - $7.99 Million	-46,386 Reduced 42.57%	62,584 $8.79 Million
Q2 2020 Aug 13, 2020	BUY	$93.0 - $171.7 $99,138 - $183,032	1,066 Added 0.99%	108,970 $17.5 Million
Q1 2020 May 06, 2020	SELL	$82.38 - $131.64 $198,782 - $317,647	-2,413 Reduced 2.19%	107,904 $10.6 Million
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $133,085 - $235,773	-1,739 Reduced 1.55%	110,317 $14.2 Million
Q3 2019 Nov 13, 2019	SELL	$72.81 - $156.91 $14,707 - $31,695	-202 Reduced 0.18%	112,056 $8.44 Million
Q2 2019 Aug 13, 2019	BUY	$112.21 - $151.95 $34,336 - $46,496	306 Added 0.27%	112,258 $17.1 Million
Q1 2019 May 14, 2019	SELL	$106.67 - $151.68 $2.22 Million - $3.16 Million	-20,815 Reduced 15.68%	111,952 $13.3 Million
Q4 2018 Feb 14, 2019	SELL	$97.32 - $148.76 $459,155 - $701,849	-4,718 Reduced 3.43%	132,767 $14.5 Million
Q3 2018 Nov 13, 2018	SELL	$115.31 - $161.51 $965,029 - $1.35 Million	-8,369 Reduced 5.74%	137,485 $22.2 Million
Q2 2018 Aug 07, 2018	BUY	$71.74 - $153.69 $50,863 - $108,966	709 Added 0.49%	145,854 $19.3 Million
Q1 2018 May 14, 2018	SELL	$54.02 - $82.27 $270,370 - $411,761	-5,005 Reduced 3.33%	145,145 $10.8 Million
Q4 2017 Feb 12, 2018	BUY	$47.64 - $56.75 $7.15 Million - $8.52 Million	150,150	150,150 $8.35 Million

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Fuller & Thaler Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Fuller & Thaler Asset Management, Inc. with notifications on news.